---
title: "OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269783673.md"
description: "Chai Discovery, a biotech startup backed by OpenAI, raised $130 million in a Series B round at a $1.3 billion valuation. Led by General Catalyst and Oak HC/FT, the round included investors like Menlo Ventures and Thrive Capital. The company, which focuses on AI-driven drug discovery, now has over $225 million in total funding. Chai Discovery aims to revolutionize drug development with its AI models, Chai 1 and Chai 2, which improve success rates in designing custom antibodies."
datetime: "2025-12-15T23:46:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269783673.md)
  - [en](https://longbridge.com/en/news/269783673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269783673.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/269783673.md) | [繁體中文](https://longbridge.com/zh-HK/news/269783673.md)


# OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation

Chai Discovery, a biotech startup with backing from OpenAI, announced an $130 million Series B round at a $1.3 billion valuation on Monday.

The round was led by General Catalyst and Oak HC/FT, the company said. Other participants include Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective. The firm’s total funding now stands at over $225 million.

The company is one in a growing industry that sees AI as a faster route towards drug development. In August, Menlo Ventures announced it was leading Chai’s $70 million Series A round. The investor described Chai as a startup that was building foundation models tuned for drug discovery, specifically to predict interactions between biochemical molecules so they could be reprogramed for cures.

Chai says that its ambition is to “build the “computer aided design suite” for molecules.” Last year, the startup announced the Chai 1 AI model and is now offering Chai 2, it’s latest model. The company says Chai 2 is achieving significant improvements in success rates over other methods for de novo antibody design, meaning building custom antibodies from scratch, not modifying existing ones.

“Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach,” Josh Meier, Chai’s co-founder and CEO said in a prepared statement.

Previously, Meier, who’s background is in machine learning, worked in research and engineering at Facebook and, prior to that, worked for OpenAI, according to his LinkedIn. Chai Discovery was founded in 2024, the profile notes.

Techcrunch event

San Francisco | October 13-15, 2026

## Related News & Research

- [Trump threatens to hit Iran 'extremely hard' over next two to three weeks](https://longbridge.com/en/news/281445712.md)
- [$100 Invested In ProShares Ultra Silver 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/281548227.md)
- [Iridium Communications Stock (IRDM) Moonshots 12% on SpaceX IPO Filing and Amazon Takeover Rumors](https://longbridge.com/en/news/281548482.md)
- [Micron Sell-off Is a "Buying Opportunity" Says Mizuho](https://longbridge.com/en/news/281560003.md)
- [Every Major Hyperscaler Is Moving To Arm — Here's Why It Matters](https://longbridge.com/en/news/281502285.md)